Psoriatic Arthritis

CLEC2B, a key gene linked to ferroptosis regulators in psoriatic arthritis, is differentially expressed in a variety of cancers and is associated with immune cell infiltration as well as immune checkpoints.

Roy M. Fleischmann, MD, and Joel M. Gelfand, MD, MSCE, FAAD, address the importance of clinician confidence in biosimilars.

Inflammatory bowel disease, including Crohn's disease and ulcerative colitis, frequently co-occurs with the immune-mediated inflammatory condition, psoriasis.

In this Q&A, Tamara van Hal, MD, discussed the findings of her study that evaluated the extent of work and activity impairment in patients with psoriatic arthritis and examined determinants associated with this impairment.

In the prospective, non-interventional SUSTAIN study, patients with active psoriatic arthritis received ustekinumab for 3 years in routine clinical care.

"Sex may play an underlying role in driving the mechanisms of psoriatic arthritis, leading to different clinical manifestations of the disease," investigators theorized.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending August 27, 2022.

"This risk-to-benefit profile has a different connotation for patients because, although a therapy may improve certain aspects of their disease, it may also have a substantial impact on their quality of life.”

Rheumatology Network interviewed Paul M. Peloso, MD, MSc, Chief Medical Officer at Acelyrin, to discuss recent phase 2 data examining the safety and efficacy of izokibep in the treatment of psoriatic arthritis.

The US Food and Drug Administration approved of the citrate-free, high-concntration (100 mg/mL) formulation of adalimumab-bwwd, a biosimilar of adalimumab, for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, plaque psoriasis, and ankylosing spondylitis.

“Given the complex nature of PsA, patients should also be involved in defining their treatment goals, as every patient may have different perspectives on the target for therapy and the means to achieve it.”

Although the current treatment strategies for children with juvenile idiopathic arthritis help to relieve pain symptoms, these medications provide limited efficacy on the underlying disease.

Serum calprotectin level may be a useful biomarker associated with a high inflammatory burden and the presence of carotid plaque.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending August 13, 2022.

Patients with psoriatic arthritis receiving risankizumab reported improved joint and skin symptoms when compared with placebo.

Results from a small study suggest that psoriatic arthritis and rheumatoid arthritis osteoclasts might retain some of their immune cell functions during differentiation.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending August 6, 2022.

Patients with pediatric psoriatic arthritis will now have access to the first-in-class treatment option, ustekinumab.

Patients with psoriatic arthritis (PsA) who have elevated interleukin-23 (IL-23) levels have been linked to higher rates of depression, anxiety, and disease activity.

“The psychosocial burden of psoriatic arthritis (PsA) has been shown to have a negative effect on the quality of life of the patients. In PsA, psychological disorders can both cause and exacerbate disease development.”

The analysis determined improvement based on a variety of clinical assessments, including the Leeds Enthesitis Index (LEI), Leeds Dactylitis Index (LDI), and modified Nail Psoriasis Severity Index (mNAPSI) scores, at baseline and week 24.

Treatment with apremilast was associated with extended time to biologic initiation when compared with treatment with methotrexate.

"COVID-19 raises special concerns regarding its course and outcome among patients with IMIDs," investigators stated.

Further research examining a possible association between smoking, which was found more frequently in nADAb-positive patients, is warranted.

Novartis announces the EC expanded on the approval of secukinumab in EU to include pediatric patients with childhood arthritic conditions: juvenile idiopathic arthritis, enthesitis-related arthritis, and juvenile psoriatic arthritis.